Encision Inc. (ECIA) Hisse Analizi
Yalnızca bilgilendirme amaçlıdır. Finansal tavsiye değildir. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
$'dan işlem gören Encision Inc. (ECIA), 0 değerindeki bir Healthcare şirketidir. Büyüme potansiyeli, finansal sağlık ve momentum konusunda 43/100 (ihtiyatlı) olarak derecelendirilmiştir.
Son analiz: 17 Mar 2026Encision Inc. (ECIA) Sağlık ve Boru Hattı Genel Bakışı
Encision Inc. is a medical device company focused on enhancing patient safety in laparoscopic surgical procedures through its patented Active Electrode Monitoring (AEM) technology. The company designs, manufactures, and markets AEM surgical instruments and monitors, primarily within the United States, utilizing a direct and independent sales network.
Yatırım Tezi
Encision Inc. presents a focused investment opportunity within the niche market of surgical safety. The company's patented AEM technology offers a potential competitive advantage by addressing the risk of stray energy burns during laparoscopic procedures. With a gross margin of 52.6%, there is potential for profitability if sales can be scaled effectively. Key growth catalysts include expanding the adoption of AEM technology in hospitals and surgical centers and introducing new AEM-integrated instruments. However, the company's small market capitalization and negative profit margin (-6.0%) indicate significant financial risks. The company's ability to increase sales and manage costs effectively will be crucial for long-term success. Monitoring the company's progress in securing new contracts and expanding its sales network will be essential for evaluating its growth potential.
FMP finansallarına ve nicel analizine dayanmaktadır
Temel Önemli Noktalar
- Encision Inc. operates in the medical device industry, specifically focusing on surgical instruments and supplies.
- The company's Active Electrode Monitoring (AEM) technology aims to enhance patient safety during laparoscopic procedures.
- Encision's product line includes AEM-integrated endo-mechanical instruments, handles, and the EndoShield 2 burn protection system.
- The company distributes its products through a network of direct and independent sales representatives in the United States.
- Encision's gross margin stands at 52.6%, indicating potential for profitability with increased sales volume.
Rakipler & Benzerleri
Güçlü Yönler
- Patented AEM technology for enhanced patient safety.
- Specialized product line focused on laparoscopic surgery.
- Direct and independent sales representative network.
- Gross margin of 52.6%.
Zayıflıklar
- Small market capitalization.
- Negative profit margin (-6.0%).
- Limited geographic reach (primarily United States).
- Dependence on a niche market.
Katalizörler
- Upcoming: Potential FDA approval for new AEM-integrated surgical instruments.
- Ongoing: Expansion of the sales network into new geographic regions.
- Ongoing: Increased adoption of AEM technology in hospitals and surgical centers.
- Upcoming: Publication of clinical studies validating the effectiveness of AEM technology.
Riskler
- Potential: Competition from larger medical device companies with greater resources.
- Ongoing: Limited financial resources and negative profit margin.
- Potential: Regulatory changes affecting medical devices.
- Ongoing: Dependence on a niche market.
- Potential: Product liability claims related to surgical instruments.
Büyüme Fırsatları
- Expansion into new therapeutic areas: Encision can explore expanding the application of its AEM technology into other surgical specialties beyond general laparoscopy. This could include areas such as gynecological surgery, urological surgery, and bariatric surgery. Each of these areas represents a significant market opportunity, potentially increasing Encision's addressable market by millions of dollars. The timeline for this expansion would involve conducting clinical studies to validate the effectiveness of AEM in these new areas, followed by regulatory approvals and targeted marketing campaigns.
- Geographic expansion beyond the United States: Currently, Encision primarily sells its products within the United States. Expanding into international markets, particularly Europe and Asia, represents a significant growth opportunity. These markets have a growing demand for advanced surgical instruments and a strong emphasis on patient safety. The timeline for international expansion would involve obtaining regulatory approvals in each target market, establishing distribution partnerships, and adapting its products to meet local market needs. This expansion could potentially double Encision's revenue within 3-5 years.
- Development of new AEM-integrated instruments: Encision can invest in the development of new surgical instruments that incorporate its AEM technology. This could include specialized instruments for specific surgical procedures or advanced instruments with enhanced features and functionality. The market for innovative surgical instruments is constantly evolving, and Encision can capitalize on this trend by introducing new products that address unmet needs. The timeline for new product development would involve conducting market research, designing and prototyping new instruments, and obtaining regulatory approvals.
- Strategic partnerships with hospitals and surgical centers: Encision can establish strategic partnerships with leading hospitals and surgical centers to promote the adoption of its AEM technology. These partnerships could involve providing training and support to surgeons, conducting joint research studies, and offering customized solutions to meet the specific needs of each institution. By building strong relationships with key stakeholders, Encision can increase its market share and establish itself as a trusted provider of surgical safety solutions. The timeline for establishing these partnerships would involve identifying key institutions, developing customized proposals, and negotiating partnership agreements.
- Increased focus on marketing and sales efforts: Encision can invest in strengthening its marketing and sales efforts to increase awareness of its AEM technology and drive sales growth. This could include expanding its sales team, attending industry conferences and trade shows, and launching targeted marketing campaigns. By effectively communicating the benefits of AEM technology to surgeons and hospital administrators, Encision can increase its market penetration and accelerate its growth trajectory. The timeline for implementing these marketing and sales initiatives would involve developing a comprehensive marketing plan, allocating resources to key activities, and tracking the results of each campaign.
Fırsatlar
- Expansion into new therapeutic areas.
- Geographic expansion into international markets.
- Development of new AEM-integrated instruments.
- Strategic partnerships with hospitals and surgical centers.
Tehditler
- Competition from larger medical device companies.
- Technological advancements by competitors.
- Regulatory changes affecting medical devices.
- Economic downturn impacting hospital budgets.
Rekabet Avantajları
- Patented Active Electrode Monitoring (AEM) technology.
- Focus on patient safety in laparoscopic procedures.
- Specialized product line of AEM-integrated surgical instruments.
ECIA Hakkında
Encision Inc., established in 1991 and based in Boulder, Colorado, is a medical device company dedicated to improving patient safety during laparoscopic surgical procedures. The company designs, develops, manufactures, and markets patented surgical instruments featuring Active Electrode Monitoring (AEM) technology. This technology is designed to minimize the risk of stray energy burns during surgery, a significant concern in laparoscopic procedures. Encision's core product line includes a range of endo-mechanical instruments such as scissors, graspers, and dissectors, all integrated with AEM. They also offer fixed-tip electrodes and suction-irrigation electrodes. These instruments are complemented by various handles designed for advanced laparoscopic procedures, incorporating stiffer shafts and ergonomic features for surgeons. Furthermore, Encision markets the AEM EndoShield 2 burn protection system and AEM monitors, which are used in conjunction with their AEM instruments to provide real-time monitoring and enhanced safety. The company distributes its products through a network of direct and independent sales representatives, primarily targeting hospitals and surgical centers within the United States. Encision's focus on AEM technology differentiates it from competitors, emphasizing safety and patient outcomes in the minimally invasive surgery market.
Ne Yaparlar
- Designs and develops surgical instruments.
- Manufactures patented surgical instruments.
- Markets surgical instruments in the United States.
- Provides Active Electrode Monitoring (AEM) surgical instruments.
- Offers AEM monitors for enhanced patient safety.
- Sells through direct and independent sales representatives.
İş Modeli
- Designs, develops, and manufactures AEM surgical instruments.
- Sells AEM instruments and monitors to hospitals and surgical centers.
- Distributes products through a network of direct and independent sales representatives.
Sektör Bağlamı
Encision Inc. operates within the medical instruments and supplies industry, a segment of the broader healthcare sector. This industry is characterized by technological innovation, stringent regulatory requirements, and a focus on improving patient outcomes. The market for laparoscopic surgical instruments is growing, driven by the increasing adoption of minimally invasive procedures. Key trends include the development of more sophisticated surgical tools, the integration of advanced technologies such as robotics and imaging, and a growing emphasis on patient safety. Encision's focus on AEM technology positions it within the patient safety segment of this market, competing with larger medical device companies and smaller specialized firms.
Kilit Müşteriler
- Hospitals
- Surgical centers
- Surgeons
Finansallar
Grafik & Bilgi
Encision Inc. (ECIA) hisse senedi fiyatı: Price data unavailable
Son Haberler
-
Encision Inc. Announces Fiscal 2026 Third Quarter Results
accessnewswire.com · 4 Şub 2026
-
Encision Deregisters Common Stock
accessnewswire.com · 29 Oca 2026
-
Stocks That Hit 52-Week Lows On Tuesday
· 24 Mar 2020
-
Stocks That Hit 52-Week Highs On Tuesday
· 24 Mar 2020
Analist Konsensüsü
Fikir Birliği Derecelendirmesi
ECIA için Benzinga, Yahoo Finance ve Finnhub'dan toplanan Al/Tut/Sat önerileri.
Fiyat Hedefleri
ECIA için Wall Street fiyat hedefi analizi.
MoonshotScore
Bu puan ne anlama geliyor?
MoonshotScore, ECIA'ın büyüme potansiyelini inovasyon, pazar yıkımı, finansal sağlık ve momentum dahil olmak üzere birden fazla faktörde 0-100 ölçeğinde derecelendirir.
Yönetim: Robert H. Fries
CEO
Robert H. Fries serves as the CEO of Encision Inc. His background includes extensive experience in managing and leading teams within the medical device industry. He is responsible for overseeing the company's strategic direction, product development, and sales and marketing efforts. His leadership is focused on driving growth and innovation within the organization.
Sicil: Under Robert H. Fries' leadership, Encision Inc. has focused on expanding its product line and strengthening its sales network. Key milestones include the development and launch of new AEM-integrated instruments and the expansion of the company's distribution partnerships. He manages a team of 22 employees.
ECIA OTC Piyasa Bilgileri
The OTC Other tier represents the lowest tier of the OTC market, indicating that Encision Inc. may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries significant risks due to the potential for limited information and increased volatility.
- OTC Katmanı: OTC Other
- Açıklama Durumu: Unknown
- Limited financial disclosure.
- Low trading volume and liquidity.
- Potential for price manipulation.
- Higher risk of fraud or mismanagement.
- Limited regulatory oversight.
- Verify the company's management team and their track record.
- Review the company's financial statements, if available.
- Assess the company's business model and competitive landscape.
- Check for any legal or regulatory issues.
- Monitor trading volume and price activity.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor.
- Company has been in business since 1991.
- Focus on patented AEM technology.
- Distribution through direct and independent sales representatives.
- Operates in the regulated medical device industry.
ECIA Healthcare Hisse Senedi SSS
ECIA için değerlendirilmesi gereken temel faktörler nelerdir?
Encision Inc. (ECIA) şu anda yapay zeka skoru 43/100, düşük puanı gösteriyor. Temel güçlü yan: Patented AEM technology for enhanced patient safety.. İzlenmesi gereken birincil risk: Potential: Competition from larger medical device companies with greater resources.. Bu bir finansal tavsiye değildir.
ECIA MoonshotScore'u nedir?
ECIA şu anda MoonshotScore'da 43/100 (Derece D) alıyor, bu da düşük derecelendirme gösteriyor. Puan, 9 kantitatif KPI genelinde büyüme potansiyelini, finansal sağlığı, piyasa momentumunu ve risk faktörlerini değerlendirir. En son piyasa verileri kullanılarak günlük olarak yeniden hesaplanır. Bu puan yalnızca bilgilendirme amaçlıdır.
ECIA verileri ne sıklıkla güncellenir?
ECIA fiyatları ABD piyasa saatleri (hafta içi 9:30-16:00 ET) sırasında gerçek zamanlı olarak güncellenir. Temeller, üç aylık veya yıllık beyanlardan sonra yenilenir. Analist derecelendirmeleri ve yapay zeka öngörüleri günlük olarak güncellenir. Haberler, finans kaynaklarından sürekli olarak toplanır.
Analistler ECIA hakkında ne diyor?
ECIA için analist kapsamı, büyük araştırma şirketlerinden fikir birliği derecelendirmelerini (al, tut, sat), 12 aylık fiyat hedeflerini ve kazanç tahminlerini içerir. Temel veri noktaları: fikir birliği hedef fiyatı, kapsayan analist sayısı, son yükseltmeler veya düşürmeler ve kazanç beklentilerini aşma/aşamama geçmişi. Bu sayfadaki Analist Konsensüsü bölümüne bakın.
ECIA'a yatırım yapmanın riskleri nelerdir?
ECIA için risk kategorileri arasında piyasa riski, şirkete özgü risk (yönetim, rekabet), finansal risk (borç, nakit yakımı) ve makroekonomik risk (oranlar, enflasyon) yer alır. Yapay zeka analizi tarafından belirlenen önemli bir risk: Potential: Competition from larger medical device companies with greater resources.. 1,0'ın üzerindeki beta, S&P 500'den daha yüksek volatiliteyi gösterir. Ayrıntılar için bu sayfadaki Risk Faktörleri bölümünü inceleyin. Tüm yatırımlar kayıp riski taşır.
ECIA'ın P/E oranı nedir?
ECIA için P/E (fiyat-kazanç) oranı, mevcut hisse senedi fiyatını hisse başına kazancıyla karşılaştırır. Daha yüksek bir P/E büyüme beklentilerini gösterebilirken, daha düşük bir P/E değer veya azalan kazançlar gösterebilir. Anlamlı bir bağlam için ECIA'ın P/E'sini sektördeki emsalleriyle ve S&P 500 ortalamasıyla karşılaştırın. Mevcut değerleme metrikleri için Finansallar sekmesini kontrol edin.
ECIA aşırı değerli mi, yoksa düşük değerli mi?
Encision Inc. (ECIA)'ın aşırı değerli mi yoksa düşük değerli mi olduğunu belirlemek, birden fazla metriği incelemeyi gerektirir. Kapsamlı bir görünüm için değerleme oranlarını (P/E, P/S, EV/EBITDA) sektördeki emsallerle karşılaştırın. Bu bir finansal tavsiye değildir.
ECIA'ın temettü verimi nedir?
Encision Inc. (ECIA) şu anda düzenli bir temettü ödemiyor veya temettü verimi verileri mevcut değil. Büyüme odaklı şirketler genellikle temettü ödemek yerine karları yeniden yatırır. En son temettü bilgileri ve ödeme geçmişi için Finansallar sekmesini kontrol edin.
Sorumluluk reddi: Bu içerik yalnızca bilgilendirme amaçlıdır ve yatırım tavsiyesi teşkil etmez. Her zaman kendi araştırmanızı yapın ve bir finans uzmanına danışın.
Resmi Kaynaklar
Veriler yalnızca bilgilendirme amaçlı sağlanmıştır.
- Limited analyst coverage for ECIA.
- OTC market carries higher risks.